Prognostic value of natriuretic peptides in Chagas' disease: A 3-year follow-up investigation

Cardiology

Volumn 110, Issue 4, 2008, Pages 217-225

  Moreira, Maria Da Consolação V ^a   Heringer Walther, Silvia ^c   Wessel, Niels ^d   Moreira Ventura, Tiago ^b   Wang, Yong ^c   Schultheiss, Heinz Peter ^c   Walther, Thomas ^c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Julia Kubitchek Hospital   (Brazil)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF POTSDAM   (Germany)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Chagas' disease; Dilated cardiomyopathy; Heart failure; Mortality

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; BLOOD SAMPLING; CHAGAS DISEASE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART VENTRICLE FUNCTION; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; CHAGAS DISEASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; STROKE VOLUME;

EID: 46349102883     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112403     Document Type: Article

References (29)

1. Chagas' disease - an epidemic that can no longer be ignored (editorial). Lancet 2006;368:619.
2. Laranja FS, Dis E, Nobrega G, Miranda A: Chagas' disease: a clinical, epidemiologic, and pathologic study. Circulation 1956;14:1035-1060.
3. Morris AS, Tanowitz HB, Wittner M, Bilezikian JP: Pathophysiological insights into the cardiomyopathy of Chagas' disease. Circulation 1990;82:1900-1909.
4. Bocchi EA: Situação atual das indicações e resultados do tratamento cirúrgico da insuficiência cardíaca. Arq Bras Cardiol 1994;63:523-530.
5. Sakata Y, Yamamoto K, Masuyama T, Mano T, Nishikawa N, Kuzuya T, Miwa T, Hori M: Ventricular production of natriuretic peptides and ventricular structural remodelling in hypertensive heart failure. J Hypertens 2001;19:1905-1912.
6. Chen HH, Burnett JC: Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000;2:198-205.
7. Walther T, Siems WE, Hauke D, Spillmann F, Dendorfer A, Krause W, Schultheiss HP, Tschope C: AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats. FASEB J 2002;16:1237-1241.
8. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G: Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003;24:1710-1718.
9. Walther T, Stepan H, Faber R: Dual natriuretic response to volume load in the fetal circulation. Cardiovasc Res 2001;49:817-819.
10. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1057-1059.
11. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek S, Packer R: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-2397.
12. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130.
13. Clerico A, Iervasi G, Pilo A: Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. Curr Drug Metab 2000;1:85-105.
14. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-1140.
15. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-e235.
16. Mathisen P, Hall C, Simonsen S: Comparative study of atrial peptides ANF (1-98) and ANF (99-126) as diagnostic markers of atrial distension in patients with cardiac disease. Scand J Clin Lab Invest 1993;53:41-49.
17. Walther T, Heringer-Walther S, Wessel N, Schultheiss HP, Moreira Mda C: Brain natriuretic peptide as a predictor of cardiomyopathy in Chagas' disease. Lancet 2003;361:1567.
18. Heringer-Walther S, Moreira MCV, Wessel N, Saliba JL, Silva-Barra J, Pena JL, Becker S, Siems WE, Schultheiss HP, Walther T: Brain natriuretic peptide predicts survival in Chagas' disease more effective than atrial natriuretic peptide. Heart 2005;91:385-387.
19. Puyo AM, Scaglione J, Auger S, Cavallero S, Donoso AS, Dupuy HA, Fernandez BE: Atrial natriuretic factor as marker of myocardial compromise in Chagas' disease. Regul Pept 2002;105:139-143.
20. Ribeiro AL, dos Reis AM, Barros MV, de Sousa MR, Rocha AL, Perez AA, Pereira JB, Machado FS, Rocha MO: Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet 2002;360:461-462.
21. Mocelin AO, Issa VS, Bacal F, Guimaraes GV, Cunha E, Bocchi EA: The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas' heart disease and idiopathic dilated cardiomyopathy. Eur J Heart Fail 2005;7:869-873.
22. Scaglione J, Puyo AM, Dupuy HA, Postan M, Fernandez BE: Behavior of atrial natriuretic factor in an experimental model of Trypanosoma cruzi infection in rats. J Parasitol 2001;87:923-926.
23. Walther T, Klostermann K, Heringer-Walther S, Schultheiss HP, Tschope C, Stepan H: Fibrosis rather than blood pressure determines cardiac BNP expression in mice. Regul Pept 2003;116:95-100.
24. Wei CM, Heublein DM, Perella MA: Natriuretic peptide system in human heart failure. Circulation 1993;88:1004-1009.
25. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M: Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000;97:4239-4244.
26. Ogawa Y, Tamura N, Chusho H, Nakao K: Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 2001;79:723-729.
27. Factor SM, Tanowitz H, Wittner M, Ventura MC: Interstitial connective tissue matrix alterations in acute murine Chagas' disease. Clin Immunol Immunopathol 1993;68:147-152.
28. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC, Chen HH, Burnett JC Jr: Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002;91:1127-1134.
29. Cho Y, Somer BG, Amatya A: Natriuretic peptides and their therapeutic potential. Heart Dis 1999;1:305-328.